Arthritis/rheumatic disorders:
Indications for: TREMFYA
Active psoriatic arthritis.
Adult Dosage:
≥18yrs: 100mg by SC inj at Weeks 0 and 4, then every 8 weeks thereafter. May be given alone or in combination with a conventional DMARD (eg, methotrexate).
Children Dosage:
<18yrs: not established.
TREMFYA Warnings/Precautions:
Use under physician supervision. May increase risk of infections. Active infection: do not initiate until resolved. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolved. Evaluate for tuberculosis (TB) infection and treat latent TB prior to initiating. Monitor for active TB during and after therapy. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Discontinue and treat if serious hypersensitivity reactions occur. Consider completion of all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.
TREMFYA Classification:
Interleukin-23 antagonist.
TREMFYA Interactions:
Concomitant live vaccines: not recommended. Concomitant CYP450 substrates with narrow therapeutic index: monitor and adjust dose as needed.
Adverse Reactions:
Upper respiratory infections, headache, inj site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, herpes simplex infections; hypersensitivty reactions.
Generic Drug Availability:
NO
How Supplied:
Single-dose prefilled syringe—1; Single-dose One-Press injector—1
Psoriasis:
Indications for: TREMFYA
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Adult Dosage:
≥18yrs: 100mg by SC inj at Weeks 0 and 4, then every 8 weeks thereafter.
Children Dosage:
<18yrs: not established.
TREMFYA Warnings/Precautions:
Use under physician supervision. May increase risk of infections. Active infection: do not initiate until resolved. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolved. Evaluate for tuberculosis (TB) infection and treat latent TB prior to initiating. Monitor for active TB during and after therapy. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Discontinue and treat if serious hypersensitivity reactions occur. Consider completion of all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.
TREMFYA Classification:
Interleukin-23 antagonist.
TREMFYA Interactions:
Concomitant live vaccines: not recommended. Concomitant CYP450 substrates with narrow therapeutic index: monitor and adjust dose as needed.
Adverse Reactions:
Upper respiratory infections, headache, inj site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, herpes simplex infections; hypersensitivty reactions.
Generic Drug Availability:
NO
How Supplied:
Single-dose prefilled syringe—1; Single-dose One-Press injector—1
